Find investors
← Back to all investors
Stephen Lestyan
ResearchedAngel Investors

Stephen Lestyan

Associate

Angel InvestorsSeed Round
Pitch Stephen

Get their honest, personalized take on your startup.

Sign in to pitch Stephen

At a glance

Full Name
Stephen R. Lestyan
Title
Vice President
Firm
Sheridan Capital Partners
Firm Type
Healthcare-focused private equity firm
Investment Stage
Lower-middle-market buyouts and growth equity
Check Size
Target equity investments of $15M-$150M for healthcare services/products and $30M-$150M for healthcare software/technology
Target Company Profile
U.S. or Canada-headquartered, founder-owned or entrepreneurially led healthcare businesses with growth, profitability, resilient end markets, recurring or re-occurring demand, fragmented markets, and limited regulatory risk
Sector Focus
Healthcare outsourced services, healthcare providers, medical products, healthcare software and technology
Geographic Focus
United States and Canada
Location
Chicago, Illinois

Background

Stephen R. Lestyan is a Vice President at Sheridan Capital Partners, a Chicago-based private equity firm focused exclusively on healthcare. His firm biography states that he was previously an Associate at Sheridan before business school, then rejoined the firm after completing his MBA.

Before Sheridan, Lestyan began his career in healthcare M&A investment banking at Harris Williams. Sheridan’s 2023 year-in-review announcement noted that Lestyan was one of four investment-team professionals added that year after completing his MBA at the University of Chicago Booth School of Business.

Lestyan earned a BSBA in Finance and Insurance & Risk Management from the University of South Carolina, where he was a Financial Scholar, and an MBA from the University of Chicago Booth School of Business. His firm bio also says he has served on the board of the Private Equity Association of Chicago and as President of the Illinois Medical District Guest House Associate Board.

Investment Thesis & Focus

  • Sheridan describes itself as “Exclusively Healthcare” and says it invests only within the healthcare industry.
  • The firm is thesis-driven: it says sector research and expertise help it “proactively identify compelling trends and attractive companies,” move quickly to close transactions, and accelerate value creation after close.
  • Sheridan targets control positions, partial recapitalizations, and buyouts in healthcare businesses and healthcare software/technology companies.
  • Target sectors include healthcare outsourced services, healthcare providers, medical products, and software/technology serving providers, payors, pharma, and patient-facing use cases.
  • For services/products, Sheridan lists target platform EBITDA of $5M-$25M and target equity investments of $30M-$150M; for software/technology, it lists target platform EBITDA of $0-$10M, revenue of $5M-$30M, and equity investments of $15M-$150M.
  • The firm prefers U.S. or Canadian companies that are founder-owned or entrepreneurially led, have consistent growth and profitability, operate in fragmented markets, and show recurring or re-occurring demand.
  • Sheridan’s value-creation model emphasizes people, process, and systems, with a dedicated Value Creation Team, functional resources, resident leadership, and strategic/executive advisors.

Notable Investments

  • Ascend Plastic Surgery Partners: Plastic surgery and aesthetics MSO formed in October 2023 through the combination of five plastic surgery practices and two MedSpas; Sheridan listed Stephen Lestyan among the deal team.
  • National Care Systems: Provider of billing, payroll, and revenue-cycle-management software for skilled nursing and assisted living facilities; Sheridan announced the investment in September 2025.
  • ICANotes: Behavioral-health EHR and practice-management software platform; Sheridan completed its investment in January 2026.
  • Currier Plastics: Custom precision plastic components manufacturer serving healthcare and life sciences customers; Sheridan invested in September 2025.
  • Tres Health: Alternative health insurance and technology company for small and medium-sized employers; Sheridan completed the investment in June 2026.
  • Focal Point Care / Future Care Consultants: Specialty RCM and technology-enabled back-office services provider for skilled nursing facilities; Sheridan partnered with Future Care Consultants in January 2023 and the business rebranded as Focal Point Care in April 2025.
  • SimiTree Healthcare Consulting: Post-acute healthcare consulting and RCM business serving home health and hospice agencies; Sheridan invested in 2021.
  • DAS Health: Managed IT services provider for healthcare providers; Sheridan invested in 2021 and realized the investment in 2025, retaining a minority stake.
  • Tarrytown Expocare Pharmacy: Long-term-care pharmacy focused on IDD and behavioral-health communities; Carlyle acquired the company from Sheridan in November 2025, with Sheridan retaining a minority position.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.